JMJ Financial is well known for our innovative Quickloans, the fastest, simplest way for growth companies to obtain unsecured capital, often within a few days, and without revenue or share price requirements. Over 250 companies have taken advantage of our Quickloan program to power their growth.
Now JMJ is offering a vastly expanded array of financial solutions, providing more issuers with more innovative financing solutions than ever before. While Quickloans utilize a convertible note structure, JMJ now offers growth and bridge financing with terms as short as six months and a variety of repayment options. JMJ has also recently completed a number of registered transactions.
For companies facing simultaneous conversions from multiple lenders, JMJ’s innovative refinance/consolidation program allows an issuer to work with a single, reputable lender, stopping those conversions while also providing additional working capital.
Loan amounts from $500,000-$3,000,000 or more are now available, every one featuring JMJ’s benchmarks of speed, flexibility, and simplicity.
“While Quickloans continue to be a cornerstone of our business, these dramatically expanded offerings have allowed us to uniquely meet the needs of a much larger spectrum of issuers,” said Sandy Weisman, Executive Vice President of JMJ Financial.
We’d be happy to discuss your company’s or client’s situation with you. As the capital we invest is the personal capital of our portfolio manager, you just might be surprised with our creativity in crafting a solution.
Selected investments are highlighted below:
$500,000: an innovative manufacturer of lithium-ion battery solutions for a variety of industrial and consumer markets.
$585,000: an alternative energy manufacturing company specializing in the conversion of bio-organic materials.
$200,000: an oil and gas exploration and development company.
$1,000,000: a developer of electrically conductive hybrid plastics used in the production of industrial, commercial, and consumer products.
$500,000: a healthcare company that operates medical clinics offering expert care in the treatment and recovery of substance abuse issues.
$650,000: a bio-pharmaceutical company engaged in the development and commercialization of targeted immune therapies.